An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Murepavadin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Polyphor
- 16 Jun 2016 Number of treatments arms changed from 5 to 6.
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
- 25 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.